Vascular Closure Device UK

The Vascular Closure Device UK Cath Labs Need

Every interventional procedure involving arterial access carries an inherent risk at the point of sheath removal. Choosing the right vascular closure device UK cath labs and interventional radiology teams can trust is essential for achieving reliable haemostasis quickly, safely, and with minimal patient discomfort. Failure to do so can result in haematoma formation, pseudoaneurysm development, prolonged bed rest, delayed discharge, and, in the most serious cases, significant vascular complications.

Gap Medical Solutions is the UK distributor for Axio, a global leader in haemostatic vascular closure technology. The Axiostat range offers chitosan-based haemostatic solutions for both radial and femoral access sites, giving cath lab teams a reliable, evidence-backed answer to post-procedural haemostasis.

Why the Right Vascular Closure Device UK-Wide Matters More Than Ever

Over the past decade, the interventional cardiology community has seen a significant shift towards transradial access (TRA) for coronary procedures. Driven by robust evidence demonstrating lower rates of access site bleeding complications, reduced major adverse cardiovascular events in high-risk populations, and improved patient comfort, TRA is now the dominant access approach in many UK centres.

However, radial access does not eliminate the need for careful haemostasis management. Radial artery spasm, radial artery occlusion, and forearm haematoma remain recognised complications, particularly when haemostasis is poorly managed or prolonged. A reliable vascular closure device UK operators can deploy confidently plays an important role in minimising these risks and supporting patient throughput.

Femoral Access: Still Essential for Complex Cases

Despite the growth of radial access, femoral access remains the approach of choice for a significant proportion of interventional procedures. Complex PCI, large-bore access for structural heart interventions such as TAVI, peripheral vascular procedures, and many interventional radiology cases continue to require femoral arterial access.

Femoral haemostasis carries a higher inherent risk of access site complications than radial, owing to the larger sheath sizes used and the anatomy of the femoral artery. The choice of vascular closure device UK teams make for femoral cases can significantly influence patient outcomes and recovery times.

Axiostat: The Vascular Closure Device UK Interventionalists Should Choose

Axiostat haemostatic dressings are based on chitosan technology. Chitosan is a naturally derived biopolymer with well-established haemostatic properties, activating the coagulation cascade and promoting rapid clot formation through electrostatic interaction with negatively charged red blood cells and platelets. Critically, this mechanism of action is independent of the patient’s intrinsic coagulation pathway, making Axiostat effective even in patients receiving anticoagulation or antiplatelet therapy.

This is a particularly significant advantage in the interventional setting, where virtually all patients are anticoagulated during the procedure and many are on long-term dual antiplatelet therapy. Axiostat’s chitosan-based mechanism helps reduce the time to haemostasis and the duration of compression required — two factors that directly affect patient experience and departmental efficiency.

Axiostat Radial Vascular Closure

Designed specifically for radial artery haemostasis following transradial access, Axiostat Radial offers a conformable, user-friendly haemostatic dressing that can be applied quickly and securely at the radial access site. The chitosan pad promotes rapid haemostasis whilst maintaining patient comfort during the compression period, supporting earlier ambulation and discharge.

Axiostat Femoral Vascular Closure

For femoral access, Axiostat Femoral provides an effective haemostatic solution that can be used alongside manual or mechanical compression. The product integrates seamlessly into existing femoral haemostasis protocols, providing an additional layer of haemostatic efficacy without complicating the post-procedural workflow.

Clinical Benefits at a Glance

• Effective haemostasis regardless of anticoagulation or antiplatelet status
• Reduced time to haemostasis compared to manual compression alone
• Lower rates of access site complications in clinical use
• Improved patient comfort during the compression period
• Supports earlier ambulation and potential for same-day discharge pathways
• Easy to use, with no complex technique or additional training required
• Available for both radial and femoral access sites

Integrating This Vascular Closure Device Into UK Cath Lab Workflows

Gap Medical Solutions works closely with cath lab managers, lead interventionalists, and procurement teams to ensure smooth integration of Axiostat products into existing workflows. We provide product training for nursing and radiographer staff, ensuring every member of the cath lab team is confident in applying and monitoring the Axiostat haemostatic dressing.

Our UK-based logistics infrastructure ensures reliable stock availability and rapid replenishment, with full supply chain transparency from our distribution hub in Gloucestershire to your department.

Supporting the Patient-First Agenda

At Gap Medical Solutions, our patient-first philosophy guides every partnership decision we make. We believe the best outcomes for patients begin with the best products, delivered with the best support. The Axiostat range exemplifies this: a clinically proven, easy-to-use vascular closure device UK interventional teams can rely on to reduce complication risk, improve patient experience, and support more efficient cath lab operations.

Frequently Asked Questions About Vascular Closure Devices UK

What makes Axiostat different from other vascular closure devices available in the UK?

Axiostat uses chitosan technology to achieve haemostasis independently of the patient’s coagulation pathway. This makes it effective even in fully anticoagulated patients, which is a significant advantage over approaches that rely on the intrinsic clotting cascade. It is also available in dedicated radial and femoral formats, covering the two most common access sites used in UK interventional practice.

Can Axiostat be used in anticoagulated patients?

Yes. Because Axiostat’s chitosan mechanism operates independently of the intrinsic coagulation cascade, it is effective even in patients who are anticoagulated or on antiplatelet therapy, making it particularly well-suited to the interventional cardiology and radiology setting.

Does Gap Medical Solutions supply Axiostat across the UK?

Yes. Gap Medical Solutions is the UK distributor for Axio products, including both the Axiostat Radial and Axiostat Femoral vascular closure ranges. We supply NHS and private hospitals across the UK from our distribution centre in Gloucestershire.

How do I request samples or a product demonstration?

Contact Gap Medical Solutions via gapmedicalsolutions.com, by email at enquiries@gapmedicalsolutions.com, or by phone on +44 (0) 1934 53 34 53. Our office is open Monday to Friday, 8:30am to 5:00pm.

Looking for a vascular closure device UK cath labs can rely on? Contact Gap Medical Solutions today or call +44 (0) 1934 53 34 53.